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Abstract Next Generation Sequencing is a technology for genome sequencing used in ge-
netics for the diagnosis of disease. NGS provides a list of all mutations in
a genome, so identifying the one that causes a disease is not trivial. A number
of applications for variant prioritization were developed, but the data they pro-
vide is a suggestion rather than a diagnosis; moreover, they suffer from issues
such as identifying a nonpathogenic variant as a causal one or the inability to
identify a causal gene. These issues inspired us to create a strategy for variant
prioritization, which includes the use of the Exomiser and OMIM Explorer
result sets improved by semantic analysis of abstracts and articles freely avail-
able from the PubMed and PubMed Central databases. For the wider scope
of scientific articles, the Google Scholar repository will be used. The described
approach enables us to present the latest and most accurate information about
potential pathogenic variants.
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1. Introduction
The information about each living organism is programmed in its DNA. DNA is a mo-
lecule composed of two coiled strands called the double helix. A DNA molecule con-
sists of smaller sections (nucleotides), which are built from sugar, a phosphate group,
and a nucleobase such as cytosine (C), guanine (G), adenine (A), or thymine (T).
The nucleobases create pairs according to the rule that C always pairs with G and
A always pairs with T [25]. The DNA strand contains many genes that are formed
in the chromosomes. Humans have 46 chromosomes. Half of them are received from
one parent and the other half come from the other. Genes consist of some number of
nucleotides and are the units of heredity. Genes can have different variants called al-
leles, which differ by one or more nucleotides. The process of creating new variations
is called mutation. Mutations lead to population variety, but it can also be a cause of
genetic diseases. Alleles can be dominant or recessive. The dominant allele is respon-
sible for the dominant phenotype. This means that this allele determines the specific
phenotype. For recessive phenotype manifestation, it is required that both copies of
the allele be recessive. If both alleles (from the mother and father) of the same gene
are the same for a particular trait they cause, the organism is called homozygous. If
the alleles are different, then it is called heterozygous. Knowledge about genes and
DNA is broadly used for genetic disease diagnostics. A contemporary technology such
as Next-Generation Sequencing enables the sequencing of the entire human genome in
one day [4]. The variety of methods allows for the selection of the most efficient and
appropriate one, like sequencing an entire genome, coding genes (a whole exome), or
analyzing only individual genes. The NGS analysis enables the gene variants respon-
sible for genetic disorders to be located; however, due to the large amount of data,
some additional analysis is required. A number of applications have been developed
in order to facilitate the search for disease-causing variants. Although the programs
employ sophisticated algorithms to compare patient data with the available genetic
databases, the results can be treated more like a suggestion than a real diagnosis.
The final list of provided pathogenic variants needs to be analyzed by a physician and
considered important or not according to a geneticist’s best knowledge. The analysis
performed by several applications also uses animal genetic databases due to the lack
of sufficient information in the human datasets. During the research performed with
Warsaw Medical University, some examples showed the limitations of variant priori-
tization programs. An Exomiser prioritization tool indicated the WSF5 variant as
a pathogenic one; however, according to the ClinVar tool, it is not a causal variant.
Another example of an Exomiser application occurred in the analysis of a patient
with a diagnosed SPATA5 variant. Although the mutation is described in PubMed
and has an entry in Online Mendelian Inheritance in Man (OMIM) with the analyzed
phenotype database, Exomiser did not indicate such a variant in its results. This issue
demonstrates that complex algorithms may not always be suitable for simple analysis.
An additional analysis that could confront variant prioritization application results
with the latest scientific knowledge is needed. Such a solution can be implemented
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as a semantic analysis tool of the PubMed database containing a broad variety of
the latest medical articles. Pointing to the latest research about a specific analyzed
genetic variant may bring a considerable advantage to the diagnosis process.
2. State of the art
Coincident with the rise of genome-wide data for diagnostics has been the develop-
ment of standards and catalogs for clinical sign-out [15,32,33]. Much of the focus has
been on distinguishing clearly deleterious variants from other variants with less clear
contributions to disease. Central to these efforts has been the development of com-
pendia for matching the observed variations to well-vetted disease information [24,26].
Some variants cataloged as “deleterious” can also appear in unaffected individuals;
therefore, additional tools have become necessary to identify the specific variants or
variant combinations such as variant pairs for recessive diseases that may explain the
observed phenotypes in affected individuals [47].
Parallel to the development of catalogs and standards for variant analysis has
been the development of systematic tools for representing patient information. Initi-
ally constructed in 2008, the Human Phenotype Ontology (HPO) is a representation
of the features of human diseases and the hierarchical relationships that exist among
them [35].
2.1. Phenomizer
A key application of this work is Phenomizer, a software tool used for making compa-
risons between known diseases and patient phenotypes [20]. This tool uses semantic
similarity methods to match patient characteristics as represented in the HPO to
the OMIM disease catalog, which is also mapped to the ontology. Phenomizer re-
turns candidates within the differential diagnosis as lists and tables, with the scores
representing the quality of the match [20].
The goal of variant prioritization is to construct an ordered ranking of an ob-
served genetic variation. This objective differs from that of a differential diagnosis,
the fundamental purpose of Phenomizer. To bridge the gap between disease ran-
kings and gene or variant rankings, extensions of this initial approach have been
developed and applied to the genome-wide diagnostic data. Two such tools are
PhenIX [26, 28, 47] and Phenomantics [28], which directly leverage the Phenomi-
zer’s semantic similarity calculation to consider the genome-wide genotypic data.
2.2. eXtasy
On the other hand, the eXtasy tool [38] takes a data-integration approach (genomic
data fusion [1]) to variant prioritization. To generate an overall prediction of causality,
ten different measures of variant deleteriousness from existing tools and databases
along with a gene haploinsufficiency prediction score are combined with a phenotype-
specific gene score. The phenotype-based method takes all disease genes known to be
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associated with a particular HPO term or terms from Phenomizer [20] and scores the
similarity of each candidate gene in the exome of this gene set using the Endeavour
algorithm [1]. Endeavour uses various measures of gene similarity, such as sequence
similarity and co-expression, as well as involvement in the same protein – protein
interactions or pathways.
A Random Forest algorithm is used to produce a single combined candidacy score
from all of these sources of evidence. For variants that are missing data from any of
the methods, an imputed score is calculated that ignores haploinsufficiency and uses
median values across all variants for the missing deleteriousness scores.
Receiver operating characteristic (ROC) analysis was used to assess the ability of
eXtasy to discriminate disease-causing variants from rare control variants or common
polymorphisms. This analysis showed substantial improvement when compared to
classical deleterious prediction methods such as PolyPhen, SIFT, MutationTaster,
and CAROL. Currently, eXtasy only performs a prioritization of non-synonymous
variants; however, when public datasets that are large enough for training become
available, it will be expanded to include mitochondrial, noncoding, synonymous, and
nonsense variants as well as mutations around the splice junction that affect splicing,
insertion, and deletion of base mutations (indels). eXtasy does not perform filtering,
so it is recommended that the exome is pre-filtered to remove off-target or common
(MAF>1%) variants [38].
2.3. Phevor
Phevor [39] takes the outputs of variant-prioritization tools such as ANNOVAR or
the Variant Annotation Analysis Search Tool (VAAST) [46] and then prioritizes the
remaining genes using phenotype, gene function, and disease data. This knowledge
comes from publicly available gene annotation sets from various biomedical ontologies
such as the HPO, Mammalian Phenotype Ontology (MPO) [10,44], Disease Ontology
(DO) [21], and Gene Ontology (GO) [7]. Users specify a list of terms from HPO, DO,
MPO, GO, or OMIM [3] that characterize what is known about the patient. Phevor
then generates a list of genes that have been annotated with these terms or their parent
terms (if no gene annotations exist). Next, it identifies terms in the other ontologies
that are annotated to these genes, and the process is repeated to expand the gene
list. Thus, concepts in different ontologies are related through their annotation of the
same gene. Finally, each gene receives a score based on the propagation of the seed
nodes in each ontology and a combination procedure across the scores from the various
ontologies. The final Phevor score combines the ranking information for the variant
prioritization tool (or P-value from VAAST) with this gene score.
The benchmarking of Phevor on simulated disease exomes based on in-house ge-
nerated exomes demonstrated a considerable improvement over variant prioritization
methods such as ANNOVAR and VAAST, with 95–100% of the exomes having the
causative variant in the top ten candidates. Three case studies where Phevor was
used to identify disease-causing alleles have also been presented [30].
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2.4. Phen-Gen
Phen-Gen [19] uses a Bayesian framework to compare the predicted deleterious vari-
ants in the patient’s exome and known patient symptoms to the prior knowledge of
human disease-gene associations and gene interactions. Coding variants are analyzed
using a unifying framework to predict the damaging impact of the non-synonymous,
splice-site, and indel variants. Phen-Gen also allows a genome-wide approach in
which evolutionary conservation and the Encyclopedia of DNA Elements (ENCODE)-
-predicted functionality and proximity to the coding sequences are used to score non-
coding variants. Any variant that has an MAF above 1% is removed from further
analysis. Healthy individuals contain many damaging mutations, and the fact that
this ability to tolerate mutations varies from gene to gene is also taken into account
using a null model. This model uses the observed variants from the 1000 Genomes
Project to generate a null distribution under either a dominant or recessive inheri-
tance model for each gene. Genes are only retained for further analysis if the predicted
damaging score for the variants exceeds that seen for 99% of the 1000 Genomes da-
taset. These remaining genes are then analyzed using the Phenomizer algorithm to
semantically match the patient’s phenotypes encoded using HPO to known disease-
gene associations. The role of the novel (non-disease) genes is assessed by identifying
functionally related genes using a random-walk-with-restart algorithm over a gene in-
teraction network. Phenotype matches are distributed to these novel genes across the
network such that the disease gene hub gets the majority of the score (90%) and
the other genes each get a share of the remainder (according to their proximity to the
disease gene). Benchmarking using the simulated exomes that were based on 1000
Genomes Project data showed that the correct disease variant was obtained as the
top hit in 88% of the samples. Using a strategy in which the known associations
were masked to simulate the discovery of novel associations, performance figures of
56% and 89% were obtained for the dominant and recessive disorders, respectively. In
an evaluation using real patient data, 11 trios with recessive or X-linked intellectual
disabilities were analyzed, and 81% of the reported genes were among the top ten
candidates [19].
2.5. Exomiser
The original implementation of Exomiser [36] used semantic similarity comparisons
between patient phenotypes and mouse phenotype data for each candidate gene in
the exome. The PhenoDigm algorithm [43] is used to score each gene from 0 to 1,
where 1 represents a perfect match, and genes with no data receive a default score
of 0.6. This phenotype score is combined with a variant score that is based on allele
rarity in the 1000 Genomes Project and ESP datasets together with the predictions
of deleteriousness from PolyPhen, SIFT, and MutationTaster. Benchmarking on the
simulated exomes based on 1000 Genomes Project data showed that 66% of the cases
had the causative variant as the top hit under a dominant model and 83% under a re-
cessive model [36]. Exomiser has been subsequently improved to include comparisons
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with human and fish phenotypes as well as the use of a random-walk with restart
to score genes with no phenotype data (genes are scored based on their proximity to
other genes in the StringDB interaction network that show phenotypic similarities
to the patient data) [42].
2.6. PhenIX
PhenIX [47] [29] uses the same software framework as Exomiser; however, instead of
using human, mouse, fish, and protein—protein association data, this tool is restricted
to comparisons between patient phenotypes and the known disease gene phenotypes.
This simplification is made because PhenIX is intended for diagnostic tasks in which
only known the disease genes can be reported. In addition, the semantic similarity
algorithm uses the Phenomizer algorithm [20]. Benchmarking on sequence files gene-
rated from a target-enrichment panel that was based on the known disease-associated
genes revealed that 97% of the samples had the inserted variant as the top hit regard-
less of the inheritance model. The same performance was observed when using 1000
Genomes Project exomes [40].
2.7. OMIM Explorer
OMIM Explorer [17] introduces an interactive approach to variant prioritization. The
implemented plots of the global and local visualizations enable the user to control
the analysis results. The patient phenotype can be input in a free-text form and is
transformed to the HPO annotation with a natural language processing tool (Bio-Lark
Concept Recognizer [16]). The genotype data should be entered in the VCF format
pre-filtered to <1% MAF (population minor allele frequency) or as a list of the main
(rare) variant genes. OMIM Explorer uses a semantic similarity method to compare
the patient phenotype to the OMIM catalog. To determine the similarity, two methods
are used: the Resnik method [31] or ATO (ancestral term overlap). Variant frequency
and pathogenicity are computed based on data from the ExAC database [11] and with
the MutationTaster tool [37]. An analysis with autosomal dominant and autosomal
recessive inheritance of the genetic disease models is available to the OE user. The
default setup applies no filter for this. An algorithm for novel disease-causing gene
discovery is also implemented in the application. First, the patient’s phenotype is
mapped to the OMIM records to receive the group of genes that causes diseases
similar to the patient’s phenotype. After that, the PINA 2.0 PPI network [8] is used
to discover the patient’s variants using the training set.
3. Technical review of Exomiser and OMIM Explorer tools
3.1. Exomiser
Exomiser [41] is an application for variant prioritization based on whole-exome sequen-
cing results. The tool analyzes genetic data provided in a Variant Call Format (VCF)
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file and a set of Human Phenotype Ontology (HPO) terms. Exomiser’s analysis con-
sists of two main parts: filtering and prioritization. First, each of the input variants
is annotated to the relative one from the hg19 database to gather information about
them. After this, the variants not required for analysis are filtered out from the da-
taset. Exomiser enables an analysis to be performed with user-defined parameters.
The two used most often are the minor allele frequency (MAF) filter (which enables
us to find the rarest variants among all variants from the input dataset) and the ex-
pected inheritance pattern filter. Three options are available for inheritance pattern
filtering: autosomal dominant (AD), autosomal recessive (AR), and X-linked (X).
The filter restricts the output data for genes containing heterozygous variants (AD),
genes containing homozygous or two heterozygous variants (AR), or X-chromosomal
genes. Exomiser also enables the possibility of family-based filtering, which requi-
res an additional input file (PED) containing family members’ genes. Prioritization
of the patient’s variants is determined based on how rarely the variant occurs in the
1000 Genomes Project [40] and Exome Sequencing Project (ESP 6500) datasets. Four
main prioritization methods are used in Exomiser. The PHIVE (Phenotypic Inter-
pretation of Variants in Exomes) algorithm uses mouse gene data as a comparison to
the human gene model. The mouse data comes from the Mouse Genome Database
(MGD) [6] and the International Mouse Phenotyping Consortium [5]. The PhenIX
algorithm is a tool for clinical diagnosis where only human data can be used. The
algorithm computes variant ranking on the basis of the pathogenicity and seman-
tic similarity of phenotypes from HPO that are connected to the Mendelian disease.
The ExomWalker algorithm is used for discovering new causal genes by searching
for the mutated genes that interact with the genes that are already implicated in
a disease. The ExomWalker employs a random walk with restart algorithm. The
random walk algorithm is a method usually used for image segmentation [14]. Having
some number of predefined labeled pixels, the unlabeled pixels are assigned to the
proper categories on the basis of the greatest probability of reaching the predefined
pixel with a random walker. Exomiser uses a similar mechanism for discovering cau-
sal genes among closely interacting genes (a mutation of any gene in such a group
will cause a similar phenotype). The user inputs the list of suspected genes, and
the algorithm calculates which mutated gene is closely related to the inputted one
in the protein-protein association network. The hiPHIVE method calculates variant
ranking using human, mouse, and zebrafish data. Human data comes from OMIM
and Orphanet databases. Zebrafish gene information comes from the Zebrafish Mo-
del Organism (ZFIN) database. To compute a variant’s ranking, Exmiser uses two
indicators: the variant and phenotype scores. The variant score is a measure that
shows the pathogenicity and frequency of the variant. Pathogenicity is calculated
on the basis of the scores from three sources: the Polyphen2, MutationTaster and 1
– SIFT scores. Frequency is determined with the use of the 1000 Genomes Project
and ESP data. The variant score result is a compounding of these two scores. If
no result can be established, the default value of 0.6 is assigned. The phenotypic
score is calculated based on the semantic similarity of the patient’s phenotype and
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phenotype-gene annotations for humans, mice, and zebrafish (for hiPHIVE). Besides
this, a random-walk algorithm is used to compare the patient’s phenotype to the re-
lated phenotypes of the nearby genes. A network for the computation is created with
the use of STRING (Search Tool for the Retrieval of Interacting Genes/Proteins).
The result of the algorithm is a probability vector with values between 0 and 1. The
values from the vector (which are the proximity scores for the analyzed genes) are
used as a weight for a phenotyping relevance score. The results are rescaled from 0 to
0.6. The final phenotypic score is computed as a maximum value from the semantic
similarity analysis and random-walk algorithm. The variant and phenotypic scores
are finally used to calculate the Exomiser Score, which is computed as follows:
ExomiserScore =
1
(1 + e(−(−13,96+11,61·PhenotypeScore+11,61·V ariantScore)))
(1)
3.2. OMIM Explorer
OMIM Explorer is an interactive web-based tool that was created for diagnostics ba-
sed on a patient’s phenotype information and genotype data. The application uses
the OMIM database and HPO to integrate and analyze the medical information.
OMIM [2] is an open-access medical database that contains human phenotypes and
genes. It is updated daily based on the published biomedical literature. All of the
entries in a database are numbered and marked according to their level of certainty
(if they are reviewed or not). The tool also provides Morbid Map and Synopsis Map
views of the relationships between the gene and the disease. HPO [35] is a database
providing a structured set of phenotype abnormality terms. The ontology was cre-
ated based on OMIM records and is broadly used by various medical applications.
Genetic and phenotypic information is provided as input data for the OMIM Explorer
application. The phenotype can be provided in a free-text form from which the HPO
terms are extracted or in a list of HPO terms. Gene information might be uploa-
ded as a VCF format file or as a list of genes. Based on the provided HPO terms,
the diagnostic disease ranking is calculated as semantic similarity, a technique that
computes matches between the queried term and the ontology. Two main methods
are used by OE: Resnik [31] and ATO (but also, ATO weighted by the GO-Universal
information and ATO weighted by annotation-based information content). The sco-
res are calculated for all OMIM diseases. They could also be restricted to those
present in an OMIM Morbidmap, the chosen genetic model (dominant or recessive),
linked to the genetic variants, or set as required by a user. To compute the results
for the inputted variant genes, the OE tool uses a transitive closure approach based
on the phenotype and disease matches. The scores are calculated only for the disea-
ses that the OMIM database maps for the input genes. The result is determined by
function F, which computes the aggregation of similarity scores of the phenotype data
diseases related to the genes. F can be a maximum, mean, or sum. For comparison,
the algorithm of the direct gene scoring approach is also used (the same as with Phe-
nomantics) as well as the method of computing the unions of phenotypes related to
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input genes by the OMIM Morbidmap (the same as with PhenIX). The data can be
analyzed as dominant or recessive genetic models. As OE is an interactive tool, two
main visualizations are available. The global one is an interactive map of all available
OMIM diseases distributed with the Multidimensional Scaling (MDS) [45] method.
The position of the patient’s disease on a chart is computed on the basis of the “m”
nearest neighbors, where “m” can be chosen by the user. Local visualization presents
the patient’s query in the center and the most similar diseases placed on the radar
according to their one-dimensional MDS results. The chart diseases are scaled based
on their variant frequency in the ExAC database [11] and colored by their variant
pathogenicity score calculated by the MutationTaster tool [37]. Visualization enables
the interactive exclusions of selected diseases from the analysis. OE has an algorithm
for novel gene and variant discovery that is generally based on the similarity of the
patient’s phenotype to OMIM entries in order to identify the set of genes mapped to
the diseases that are most similar to the patient’s query. After this step, the PINA
2.0 PPI [8] network is used to discover the candidate genes. OMIM Explorer also
provides additional features (like phenotype suggestions) based on rare phenotypes
that are not present in a patient’s query but are annotated as most similar to the
patient’s disease.
4. Authors’ solutions to Next Generation Sequencing
results analysis
4.1. Implementation of Exomiser as Cloud Service
The main goal of this research was to provide Warsaw Medical University (WUM) with
a usable genetic diagnostic tool. Because most research conducted on scientific NGS
was not necessary, the main problem was the data filtration in order to provide robust
and accurate results that would be highly related to only potential human diseases.
It was not possible to return adequate information about gene mutation in other
species. First, the Exomiser tool was used and a special tool implemented in order to
carry on user queries in an automatic manner. Unfortunately, the results provided by
Exomiser were not accurate, and a lot of noisy data was provided. The experiments
were conducted on eight random and anonymous sequenced gene samples provided
by the WUM. Table 1 presents the number of results provided by the Exomiser tool
without any modifications.
As presented in Table 1, such an enormous number of potential results makes it
very hard or even impossible for a doctor to make the right diagnosis in an affordable
amount of time. Also, the accuracy of such results is very low. This is why we were
able to adjust adequate filtering strategies for such an analysis in an empirical study
based on the patient’s HPOs and doctor’s suspicions. First of all, as a pre-analysis
step, we removed the synonymous gene variants, intron variants, and intergenic va-
riants (coding and non-coding). Because disease-causing mutations are rare, we also
filtered the sequenced input variants by frequency.
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Table 1
Number of results provided by Exomiser with adjusted filtering strategy
Sample ID Number of results
1 18
2 15
3 15
4 23
5 19
6 17
7 12
8 18
When conducting an autosomal dominant analysis, the maximum frequency was
set to 0.0001; for the autosomal recessive 0.3; and for the X recessive 0.0003 [27]. We
also removed the results with a prioritization score lower than 0.5 using the HiPhive
prioritization algorithm [18]. With this strategy, we greatly reduced the number of
results (as presented in Table 2).
Table 2
Number of results provided by Exomiser without modifications
Sample ID Number of results
1 1462
2 1375
3 2034
4 1653
5 3261
6 1742
7 1274
8 1563
Because not all of the results were known to be pathogenic, we annotated the re-
sults in accordance to the ClinVar database that archives and aggregates information
about relationships among variations and human health [24]. Unfortunately, the re-
sults were only partially satisfactory. While some results correlated with the doctor’s
judgments and some were potentially interesting because of the correspondence with
other species, they were not analyzed enough to be treated as diagnoses. Because of
this, a trial was made to use the most recent OMIM Explorer tool. OMIM Explorer
did not encounter as many resultant pathogenic variants as Exomiser. The analysis
was performed with the default application settings. No inheritance model was cho-
sen. The input VCF [9] file for OMIM Explorer needs to be pre-filtered with MAF.
Files that contain more than 100,000 rows are not processed by the program. The
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experiment was provided with the same set of patient data as used in Exomiser. In
Table 3, we present the number of results provided by OMIM Explorer.
Pathogenic variants returned by OE-overlapped Exomiser only results in a small
range, with a maximum number of two common variants and a minimum of zero
similar results.
Table 3
Number of results provided by OMIM Explorer
Sample ID Number of results
0 16
1 19
2 12
3 15
4 14
5 19
6 15
7 14
8 13
The OMIM Explorer tool is a web application that requires direct user engage-
ment in the analysis process. To simplify the use of OE, the web crawler tool was
developed. A script enables the VCF file to be provided as well as the phenotype as
a list of HPO terms. Such an approach will also facilitate an automatic comparison
of the different variant prioritization application results. Both OMIM Explorer and
Exomiser suffered very similar drawbacks. We also discovered that some recently dis-
covered diseases causing gene mutations were not or gene mutations that no longer are
considered to be problematic for human health were within the prioritization results.
In a real-life diagnosis, such mistakes should not appear and the databases should be
as current as possible.
4.2. Semantical human-genetic diagnoser (HGD)
The problems described in Section 4.1 made us prepare more-sophisticated diagnosis
strategies. First, we interpolated the results of Exomiser and OMIM Explorer. Se-
cond, we developed a semantic text analysis tool accompanied with web crawlers in
order to analyze scientific research articles. For this purpose, a sophisticated search
engine (ElasticSearch) was used [13]. At first, our web crawlers downloaded abstracts
from the PubMed repository (only abstracts, which are freely available) [22], and
facilitated articles and supplementary files freely available in the PubMed Central
database [34]. Third, using the Python tool we implemented with the ElasticSearch
engine, we queried those repositories using the diagnosed HPO’s and genes prioriti-
zed with Exomiser and OMIM Explorer. Our search engine semantically analyzed
abstracts, articles, and supplementary files. Not only was the HPO-gene relationship
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queried, but the publication release date, number of keyword hits, and number of
citations were also taken into account [23]. In addition, we also queried the Google
Scholar repository (which has a wider scope) and interpolated both search results [12].
Lastly, having the search results gathered, we altered the prioritization results in ac-
cordance with the findings. The most-relevant results were at the top of the list,
whereas irrelevant or out-of-date results were removed. If no very accurate answer
could be given to the user, the tool provided him/her with a list of articles that corre-
late with the disease for his/her own judgment. Such a methodology allows users to
receive up to five relevant results in most cases. The current version of our semantic
text analysis provides a web browser searching interface. Simple logical operations of
conjunction and disjunction can be applied to a query. Moreover, a user-defined slop
is available for use. Slop describes how the searched terms can be distant from each
other in an article. a slop with a value of 1 allows for at most one additional word
placed between the searched words. The default value for the slop in our tool is 5.
A returned-results score is presented as a graphical star ratio.
4.3. Authors’ motivation
The aim of our work is to support the process of diagnosing patients with genetic dise-
ases. The solution we developed facilitates two difficulties in the diagnoses: the huge
amount of data provided by the Next Generation Sequencing process, and the great
number of scientific articles published in the genetic area. We use stable and reliable
tools to provide the most-probable causal variants from the input data. It provides
suggestions for the doctor regarding which variants needs to be analyzed first. The
list of causal variants is verified with the scientific articles from the PubMed reposi-
tory. The doctor can decide whether the proposed variant is valuable for the diagnosis
and the knowledge about the variant could be completed. The solution allows for an
automatic data analysis. The process of diagnosis can be faster and more efficient,
which brings benefits to the doctors and patients because the treatment can be started
earlier. The doctor does not need to analyze a huge amount of data. Supported by
knowledge from scientific papers, the diagnosis could be more precise and accurate.
5. Results and conclusions
In an experiment with our HGD tool, we used nine anonymous VCF files [9] that were
first analyzed with the Exomiser and OMIM Explorer applications. The Exomiser
settings and filters were set with the values described in Section 4.1 of this article. The
OMIM Explorer analysis was run with default OE settings. The same HPO terms
were provided to both tools. Exomiser usually returned a slightly larger number
of suggested pathogenic variants than OMIM Explorer did. The comparison of the
two resultant sets of each sample revealed that some variant suggestions appeared
in both resultant sets. The number of overlapping results was usually not greater
than two; for one sample, the application returned divergent results. Table 4 presents
detailed information about the number of returned results for the analyzed samples.
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Table 4
Number of variants returned by Exomiser and OMIM Explorer for analyzed samples
Sample ID Exomiser OMIM Explorer Overlapping variants
0 24 16 2
1 16 19 1
2 21 12 1
3 22 15 0
4 25 14 2
5 24 19 2
6 30 15 1
7 30 14 1
8 21 13 1
Each of the resultant variants was provided to the semantic text analysis tool in
order to retrieve the related PubMed articles. The retrieval was performed according
to three patterns: with the variant name only, with the variant name and one or more
of the patient’s phenotype terms, or with the variant name and all of the phenotype
terms. Table 5 presents the average and medium numbers of returned articles for
each sample based on the set of variants outputted by Exomiser and OMIM Explorer.
The calculation was created taking into account the numbers of articles found in the
PubMed and PubMed Central databases for each variant (returned by Exomiser or
OE) for each sample.
Table 5
Average and median number of PubMed articles returned by HGD from Exomiser and OMIM
Explorer resultant variants
ID
Exomiser OMIM Explorer
Variant Variant and Variant and Variant Variant and Variant and
only any HPO all HPO only any HPO all HPO
Avg Med Avg Med Avg Med Avg Med Avg Med Avg Med
0 497 365 10 4 2 0 3433 314 77 12 7 2
1 1591 485 29 4 2 1 926 312 39 20 6 2
2 1183 419 18 7 2 1 911 582 62 27 8 2
3 1114 290 18 4 2 0 535 171 51 23 7 2
4 740 317 20 5 3 1 1383 496 112 36 19 5
5 2367 338 38 5 3 0 946 299 33 17 3 1
6 408 249 7 3 0 0 1772 255 61 19 11 3
7 652 276 18 4 3 0 789 386 62 32 11 3
8 381 145 8 2 1 0 1147 898 74 36 12 2
The more accurate the query returns, the smaller the number of articles. Adding
phenotype requirements to the computation decreased the number of returned results.
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Some cases showed a surprisingly large number of returned articles, even with precise
queries. This was usually caused by the fact that the genetic variant name was the
same as that of another medical term, which increased the result set.
The analysis that required the presence of the variant name and all pathogenic
terms in the article returned the smallest number of PubMed articles. In this analysis
pattern, the majority of the cases had fewer than five related papers. Only about 20%
of the variants provided by Exomiser (Figure 1) for a chosen sample and about 30%
in OMIM Explorer (Figure 2) had five or more articles found in PubMed, which may
indicate that they could be analyzed first in the diagnostic process.
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Figure 1. Relationship of number of PubMed articles returned by HGD analysis with variant
and all phenotype terms for Exomiser resultant variants
A similar operation was performed with the Google Scholar repository. As was
expected, Google Scholar returned many more articles than our HGD semantic search
module. The average and median calculations of the article numbers for the analyzed
samples are presented in Table 6.
The differences between the number of found articles by the search tools are quite
large. Google Scholar searches for a given expression in a wide variety of sources, not
only among openly available articles but also in scientific journals where a subscription
is necessary. Besides that, Google Scholar uses a mechanism that improves searching
by looking for similar-looking words, which is not always desirable in the case of
genetic variant names because it generates a lot of article suggestions that are not
related to the searched subjects. Google Scholar searches more than just medical
journals, which also contributes to the increase in the number of suggested articles.
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Figure 2. Relationship of number of PubMed articles returned by HGD analysis with variant
and all phenotype terms for OMIM Explorer resultant variants
Table 6
Average and median number of PubMed articles returned by HGD semantic search
mechanism from Exomiser and OMIM Explorer resultant variants
ID
Exomiser OMIM Explorer
Variant Variant and Variant and Variant Variant and Variant and
only any HPO all HPO only any HPO all HPO
Avg Med Avg Med Avg Med Avg Med Avg Med Avg Med
0 41707 5370 1677 81 1301 12 692694 4595 5774 216 1609 54
1 169751 6255 1850 254 1464 43 78622 5510 1858 413 1947 95
2 95970 7010 1031 130 1345 40 98434 6085 2383 422 1552 108
3 52511 7125 1305 76 1001 19 49284 2130 2038 413 1250 120
4 25056 5140 433 133 1925 40 136539 6105 3707 437 1800 180
5 152441 4600 1253 89 186 17 15184 4780 705 303 536 95
6 53116 5510 354 75 1247 17 241357 6370 1323 467 1965 125
7 12184 5700 673 80 535 18 99423 4415 758 349 364 74
8 71355 2270 582 60 836 8 202310 6020 3294 543 3534 157
After combining the Exomiser and OMIM Explorer results with the articles re-
turned by HGD and GoogleScholar, it is noticeable that the variants present in both
variant prioritization tool’s result sets have quite a large number of returned arti-
cles. The numbers are usually above the medians presented in Tables 5 and 6. This
indicates that the known and well-studied variants were proposed by the tool.
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For each analyzed sample, the variants present in both the OMIM Explorer and
Exomiser resultant sets were provided to semantic search tools (HGD and Google
Scholar) with a patient’s phenotype terms. As the input for the search, two approaches
were chosen: variant name with all phenotype terms required and variant name with
at least one of the provided phenotype words required. The results are presented in
Table 7.
Table 7
Number of articles found by HGD and GoogleScholar for variants present in OE and Exomiser
result sets for provided samples
SampleID
Variant
name
HGD GoogleScholar
Variant and Variant and Variant and Variant and
any HPO all HPO any HPO all HPO
0
WFS1 76 14 677 211
PLIN1 13 4 159 40
1 CDKN1C 51 7 625 164
2 CYP21A2 16 1 409 125
3 – – – – –
4
ABCC8 211 45 2200 1370
GNAS 41 4 543 157
5
ALMS1 31 7 303 75
CPT2 58 5 761 242
6 MC2R 33 2 563 133
7 ABCC8 211 45 2200 1370
8 GNAS 41 4 543 157
The strategy where the doctor searches for the pathogenic variant name and
at least one of the phenotype terms is the most likely one. Therefore, this case is
presented in Figure 3. The median number of articles found for one variant in the ‘OR
strategy’ by Google Scholar is 137, but half of the results are numbers between 45 and
622. Reading and manually analyzing all of the available articles might be difficult.
As its repository is much smaller, HGD returns a median number of 7 articles, but the
values of the first and third quartiles are 2 and 22, respectively. Reading or inspecting
such a number of articles is time-consuming. If the doctor decides to verify all of the
variants returned by the algorithms, the presented numbers need to be multiplied by
the median number of returned variants by Exomiser and OMIM Explorer (which
is 39). The overall number of articles found by the geneticist in GoogleScholar will
exceed a thousand. HGD will return about 300 or more articles; thus, a manual
analysis of such a large number of papers is not possible. A strategy for prioritizing,
filtering, and choosing valuable articles is required. The results of the experiment
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show that the proper filtering strategy for variant prioritization can bring a great
reduction in the number of potentially causal variants. The diagnosis is mostly made
based on the doctor’s experience and knowledge, but the information and discoveries
delineated in the scientific articles is also important. An analysis of the scientific
articles is important. Due to the large number of sources, the fast development and
increased research in the area of a manual analysis of every potentially valuable paper
might be difficult.
Figure 3. Numbers of articles returned by Google Scholar and HGD for one variant and at
least one phenotype term
The research on the HGD tool presented in this article is a strategy that is going
to be developed. The solution requires additional medical and technical analyses with
diagnosed samples. Currently, the analyzed samples require final medical diagnosis,
which will also verify the HGD application approach and review the idea of variant
scoring.The performed experiments revealed a number of challenges to meet in further
HGD research. Including ExomiserScore and OMIM Explorer, the calculated mea-
sures will improve the calculation of most highly pathogenic variants, especially for
those samples where the results returned by Exomiser and OE do not have common
values. A semantic search performed by HGD requires us to include scientific arti-
cle publication dates into the scoring. The solution should also exclude the articles
that are not from the genetic field and are presented in the result list because of the
similarity between medical terms.
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